Inventor · disambiguated record
Lingyun Rui
Also filed as: RUI LINGYUN
35 granted patents·16 pending applications·412 citations·filing 2011–2025
98Inventor score
Top patents by PatentIndex Score
51 records- 0197US10752683B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2019·Granted Aug 25, 2020·13 cites·31 claims
- 0297US9670279B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Jun 6, 2017·26 cites·118 claims
- 0397US9133275B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2013·Granted Sep 15, 2015·45 cites·44 claims
- 0496US9670280B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Jun 6, 2017·19 cites·74 claims
- 0596US9670278B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Jun 6, 2017·18 cites·104 claims
- 0696US9657100B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted May 23, 2017·16 cites·40 claims
- 0796US9598490B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Mar 21, 2017·18 cites·40 claims
- 0896US8557966B2Folate receptor 1 antibodies and immunoconjugates and uses thereofAB OLGA·Filed 2011·Granted Oct 15, 2013·89 cites·20 claims
- 0995US8765917B2CD37-binding molecules and immunoconjugates thereofDECKERT JUTTA·Filed 2011·Granted Jul 1, 2014·31 cites·26 claims
- 1094US10875925B2Anti-CD123 antibodies and conjugates and derivatives thereofIMMUNOGEN INC·Filed 2020·Granted Dec 29, 2020·3 cites·12 claims
- 1194US10077313B2Anti-CD123 antibodies and conjugates and derivatives thereofIMMUNOGEN INC·Filed 2016·Granted Sep 18, 2018·12 cites·28 claims
- 1294US10017578B2Methods of treating cancer in a patient by administering anti-folate-receptor-1 (FOLR1) antibodiesIMMUNOGEN INC·Filed 2017·Granted Jul 10, 2018·12 cites·29 claims
- 1394US9346887B2CD37-binding molecules and immunoconjugates thereofIMMUNOGEN INC·Filed 2013·Granted May 24, 2016·12 cites·41 claims
- 1493US11332535B2Anti-CD123 antibodies and conjugates and derivatives thereofIMMUNOGEN INC·Filed 2020·Granted May 17, 2022·2 cites·14 claims
- 1593US11198736B2Method for identifying an ovarian cancer in a subject likely to respond to anti-folate receptor 1 (FOLR1) antibodyIMMUNOGEN INC·Filed 2019·Granted Dec 14, 2021·5 cites·28 claims
- 1693US10919969B2Anti-CD123 antibodies and conjugates and derivatives thereofIMMUNOGEN INC·Filed 2017·Granted Feb 16, 2021·4 cites·4 claims
- 1793US10301385B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2017·Granted May 28, 2019·8 cites·28 claims
- 1893US9637547B2Monoclonal antibodies for detection of folate receptor 1IMMUNOGEN INC·Filed 2014·Granted May 2, 2017·15 cites·36 claims
- 1993US8790649B2EGFR-binding molecules and immunoconjugates thereofSETIADY JULIANTO·Filed 2011·Granted Jul 29, 2014·26 cites·37 claims
- 2092US12152060B2Interleukin-2 variants and methods of uses thereofCUGENE INC·Filed 2023·Granted Nov 26, 2024·1 cites·6 claims
- 2192US11932701B2Method for increasing the efficacy of cancer therapy by administering an anti-FOLR1 immunoconjugateIMMUNOGEN INC·Filed 2021·Granted Mar 19, 2024·1 cites·19 claims
- 2290US10202460B2CD37-binding molecules and immunoconjugates thereofDEBIOPHARM INT SA·Filed 2016·Granted Feb 12, 2019·7 cites·22 claims
- 2389US11466095B2CD37-binding molecules and immunoconjugates thereofDEBIOPHARM INT SA·Filed 2018·Granted Oct 11, 2022·3 cites·21 claims
- 2489US2024132585A1Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2023·Application pending·0 cites
- 2588US11634467B2Cytokine-based bioactivatable drugs and methods of uses thereofCUGENE INC·Filed 2019·Granted Apr 25, 2023·3 cites·9 claims
- 2688US10544230B2Methods of using antibodies to detect folate receptor 1 (FOLR1)IMMUNOGEN INC·Filed 2018·Granted Jan 28, 2020·4 cites·25 claims
- 2788US10442865B2Methods of use of anti-CD123 antibodies and antigen-binding fragments thereofIMMUNOGEN INC·Filed 2018·Granted Oct 15, 2019·4 cites·16 claims
- 2888US2024360240A1Antibodies and assays for detection of folate receptor 1IMMUNOGEN INC·Filed 2024·Application pending·0 cites
- 2985US9173961B2CD20 antibodies and uses thereofDECKERT JUTTA·Filed 2011·Granted Nov 3, 2015·8 cites·32 claims
- 3081US11897961B2Anti-CD123 antibodies and conjugates and derivatives thereofIMMUNOGEN INC·Filed 2022·Granted Feb 13, 2024·0 cites·11 claims
- 3180US12319723B2Cytokine-based bioactivatable drugs and methods of uses thereofCUGENE INC·Filed 2023·Granted Jun 3, 2025·0 cites·9 claims
- 3280US9125896B2EGFR-binding molecules and immunoconjugates thereofIMMUNOGEN INC·Filed 2013·Granted Sep 8, 2015·3 cites·39 claims
- 3379US11104740B2Antibodies and assays for detection of CD37DEBIOPHARM INT SA·Filed 2016·Granted Aug 31, 2021·2 cites·19 claims
- 3477US2024254185A1Interleukin-2 variants and methods of uses thereofCUGENE INC·Filed 2024·Application pending·0 cites
- 3576US2025326812A1Cytokine-based bioactivatable drugs and methods of uses thereofRUI LINGYUN·Filed 2025·Application pending·0 cites
- 3676US2024190956A1Conjugates comprising cell-binding agents and cytotoxic agentsIMMUNOGEN INC·Filed 2023·Application pending·0 cites
- 3775US10988531B2Conjugates comprising cell-binding agents and cytotoxic agentsIMMUNOGEN INC·Filed 2015·Granted Apr 27, 2021·1 cites·11 claims
- 3875US2021032327A1Folate Receptor 1 Antibodies and Immunoconjugates and Uses ThereofIMMUNOGEN INC·Filed 2020·Application pending·0 cites
- 3972US9238690B2Non-antagonistic EGFR-binding molecules and immunoconjugates thereofSETIADY JULIANTO·Filed 2011·Granted Jan 19, 2016·1 cites·38 claims
- 4070US11732038B2Conjugates comprising cell-binding agents and cytotoxic agentsIMMUNOGEN INC·Filed 2021·Granted Aug 22, 2023·0 cites·6 claims
- 4169US12319722B2Interleukin-15 (IL-15) fusion proteins and uses thereofCUGENE INC·Filed 2019·Granted Jun 3, 2025·0 cites·12 claims
- 4266US2025388641A1Novel interleukin-15 (il-15) fusion proteins and uses thereofCUGENE INC·Filed 2025·Application pending·0 cites
- 4358US2021269497A1Interleukin-2 variants and methods of uses thereofCUGENE INC·Filed 2019·Application pending·0 cites
- 4452US2022170028A1Novel interleukin-2 variants and bifunctional fusion molecules thereofCUGENE INC·Filed 2020·Application pending·0 cites
- 4552US2023048046A1Novel interleukin-15 (il-15) fusion proteins and uses thereofCUGENE INC·Filed 2020·Application pending·0 cites
- 4652US2023093155A1Cytokine-based bioactivatable drugs and methods of uses thereofCUGENE INC·Filed 2020·Application pending·0 cites
- 4751US2022235109A1Novel interleukin-2 variants for the treatment of cancerCUGENE INC·Filed 2020·Application pending·0 cites
- 4848US2016060345A1Novel EGFR-Binding Molecules and Immunoconjugates ThereofIMMUNOGEN INC·Filed 2015·Application pending·0 cites
- 4947US2016017053A1Non-Antagonistic EGFR-Binding Molecules and Immunoconjugates ThereofIMMUNOGEN INC·Filed 2015·Application pending·0 cites
- 5043US2016108126A1CD20 Antibodies and Uses ThereofIMMUNOGEN INC·Filed 2015·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Lingyun Rui files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →